Altimmune, Inc. (ALT) vs Oculis Holding AG (OCS)
- Altimmune, Inc. ALT 2.20 −6.78%
- Oculis Holding AG OCS 7.29 −1.49%
Altimmune, Inc. and Oculis Holding AG are both Biotechnology companies. Altimmune, Inc. and Oculis Holding AG are of similar size ($459.1M and $456.8M). Altimmune, Inc. grew revenue faster over the last twelve months: 130.0% against 65.8%. Altimmune, Inc. has the higher net margin (0.00% vs −6,870.1%) and the lower return on invested capital (−34.3% vs 0.00%). Across the 16 metrics below, Altimmune, Inc. leads on 10 and Oculis Holding AG on 6.
Valuation
Profitability
| Metric | ALT | OCS | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | 0.00% | (7,383.66%) | 0.00% |
| Net margin | 0.00% | (6,870.05%) | 0.00% |
| Free cash flow margin | 0.00% | (5,525.64%) | 0.00% |
| Return on equity | (28.87%) | (44.87%) | (56.36%) |
| Return on assets | (25.58%) | (37.69%) | (48.04%) |
| Return on invested capital | (34.30%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack